JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pönicke, K.
Right arrow Articles by Brodde, O.-E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pönicke, K.
Right arrow Articles by Brodde, O.-E.

Vol. 301, Issue 1, 71-76, April 2002

Differential Effects of Bucindolol and Carvedilol on Noradenaline-Induced Hypertrophic Response in Ventricular Cardiomyocytes of Adult Rats

Klaus Pönicke, Ingrid Heinroth-Hoffmann and Otto-Erich Brodde

Institute of Pharmacology, Martin-Luther-University of Halle-Wittenberg, Halle, Germany

In adult rat ventricular cardiomyocytes, noradrenaline exerts dual effects on protein synthesis: increases via alpha 1-adrenoceptors and decreases via beta 1-adrenoceptors. Carvedilol and bucindolol are beta -blockers with additional alpha 1-adrenoceptor blocking activities. We studied the effects of carvedilol and bucindolol on noradrenaline-induced protein synthesis (assessed by [3H]phenylalanine incorporation) in adult rat ventricular cardiomyocytes. Radioligand binding studies with [125I]iodocyanopindolol and [3H]prazosin revealed that carvedilol had a much higher affinity to alpha 1-adrenoceptors than bucindolol (beta 1-/alpha 1-adrenoceptor ratio for carvedilol, 1:2.7; for bucindolol, 1:43). Noradrenaline-evoked increases in protein synthesis were enhanced by propranolol (1 µM) and beta 1-adrenoceptor-selective antagonists bisoprolol (1 µM) and CGP 20712A [1-[2-((3-carbamoyl-4-hydroxy)phenoxy)-ethyl-amino]-3-[4-(1-methyl-4-trifluoromethyl-2-imidazolyl)phenoxy]-2-propranol methanesulfonate] (300 nM). Carvedilol (100 pM-10 µM) inhibited 1 µM noradrenaline-induced increase in protein synthesis with monophasic concentration-inhibition curves independent of whether CGP 20712A was present or not; Ki values for carvedilol were 5 to 6 nM. In contrast, bucindolol (100 pM-10 µM) inhibited l µM noradrenaline-induced increase in protein synthesis with a bell-shaped concentration-inhibition curve; it increased noradrenaline-induced protein synthesis at 10 nM, although at concentrations >100 nM it was inhibited. In the presence of 300 nM CGP 20712A or 1 µM propranolol, however, bucindolol inhibited 1 µM noradrenaline-induced increase in protein synthesis with monophasic concentration-inhibition curves; Ki values were 40 to 75 nM. On the other hand, both carvedilol and bucindolol inhibited 1 µM phenylephrine-induced protein synthesis with monophasic concentration-inhibition curves; Ki values were 4 (carvedilol) and 45 nM (bucindolol). These results indicate that, at low (beta -adrenoceptor blocking) concentrations, bucindolol can enhance noradrenaline-induced protein synthesis whereas it is inhibited by carvedilol.


0022-3565/02/3011-0071$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
A. Salameh, S. Krautblatter, S. Baessler, S. Karl, D. R. Gomez, S. Dhein, and D. Pfeiffer
Signal Transduction and Transcriptional Control of Cardiac Connexin43 Up-Regulation after {alpha}1-Adrenoceptor Stimulation
J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 315 - 322.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Galandrin and M. Bouvier
Distinct Signaling Profiles of beta1 and beta2 Adrenergic Receptor Ligands toward Adenylyl Cyclase and Mitogen-Activated Protein Kinase Reveals the Pluridimensionality of Efficacy
Mol. Pharmacol., November 1, 2006; 70(5): 1575 - 1584.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K.-D. Schluter and K. C Wollert
Synchronization and integration of multiple hypertrophic pathways in the heart
Cardiovasc Res, August 15, 2004; 63(3): 367 - 372.
[Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.